Current Situation Analysis on Adverse Drug Reaction Reporting and Monitoring in Our Country

Abstract

HU Wen-jun, CAI Ji-fen. Current Situation Analysis on Adverse Drug Reaction Reporting and Monitoring in Our Country[J]. Chinese Journal of Pharmacovigilance, 2012, 9(2): 92-94.

[1] 卫生部.药品不良反应报告和监测管理办法[S].卫生部令第81号,2011-05-04.
[2] 中华人民共和国.中华人民共和国侵权责任法[S].中华人民共和国主席令第21号,2009-12-26.
[3] 钱之玉主编.药理学进展[M].南京：东南大学出版社,2005,5：433-443.
[4] 中华人民共和国.中华人民共和国药品管理法[S].中华人民共和国主席令第45号,2001-02-28.
[5] 国家食品药品监督管理局.关于2006年全国药品不良反应病例报告情况的通报[S].国食药监安[2007]47号,2007-01-23.
[6] 国家食品药品监督管理局.关于定期汇总报告和进口药品境外发生的药品不良反应报告有关问题解释的通知[S].国食药监安[2005]89号,2005-02-25.
[7] 邢蓉,鄂眉.中美两国药品不良反应监测状况的比较[J].中国现代药物应用,2010,4(10)：230-232.
[8] 沈金芳,张忠平,逄晓云,等.药品不良反应监测工作的实施经验[J].中国医院药学杂志,2006,23(3)：333-34.
[9] 80 Postmarketing reporting of adverse experiences[R].The Code of Federal Regulations,FDA,USA,21CFR600：80 Sec,600.
[10] 80 Postmarketing reporting of adverse drug experiences[R].The Code of Federal Regulations,FDA,USA,21 CFR3 14,80 Sec：314.
[11] 上海市临床药品不良反应监测中心.医疗单位药物警戒工作的回顾与前瞻[J].药学服务与研究,2001,1(1) ：46-48.
[12] 中华人民共和国.中华人民共和国产品质量法[S].中华人民共和国主席令第33号,2000-07-08.
[13] 李龙.国外药品不良反应救济制度简述 [J].国际医药卫生导报,2005,11：91-93.
[14] 李一标,朱舒兵,成戎川,等.关于设立我国药品不良反应受助基金的建议[J].中国药业,2009,19（16）：2.
[15] 郭志鑫,黄志禄,姜典财,等.中日美药品上市后质量评价体系的比较[J].中国药事,2009,23（7）：718-720.

Current Situation Analysis on Adverse Drug Reaction Reporting and Monitoring in Our Country

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[2]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[3]	GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
[4]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[5]	LIU Qian, HU Jing, LI Bo, YANG Xiaojing. Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
[6]	HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia. 535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
[7]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[8]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[9]	ZHANG Lei, LYU Jian, XIE Yanming. Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
[10]	LIU Jingjing, DAI Zhong, YANG Jianbo, WANG Ying, XU Beilei, LIU Yue, WANG Qi, MA Shuangcheng. Spectrum-fect relationship of Ginseng Radix et Rhizoma Rubra and Polygonum Multiflorum Radix Preparata medicinal pair in protection of nerve cells [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 623-628.
[11]	CHEN Xiao, GUO Xiaojing, XU Jinfang, WEI Lianhui, CHEN Chenxin, LIANG Jizhou, ZHENG Yi, YE Xiaofei. Machine learning method in the detection of adverse drug reaction signals of brigatinib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 639-645.
[12]	ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei. Discuss the safety management of medical toxic drugs in medical institutions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708.
[13]	LIU Baosheng, WANG Guanjie, WANG Zhenhua, LIU Lihong, ZHU Yan, ZHOU Xiuli. One case of acute liver injury caused by tripterygium glycosides tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 511-513.
[14]	CHENG Fengjingming, LYU Jian, XIE Yanming. Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543.
[15]	WANG Guohua, LI Xiaolei, LIU Xiping, DONG Yizhi, ZANG Chen, XU Hong, TIAN Jixiang, ZHAO Jing. Aerosol inhalation of Tanreqing injection in the treatment of chronic obstructive pulmonary disease: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 544-552.